Therapeutic effect of irbesartan combined metoprolol on patients with chronic heart failure complicated atrial or ventricular arrhythmia／ / 心血管康复医学杂志

ABSTRACT

To explore therapeutic effect of irbesartan combined metoprolol on patients with chronic heart failure (CHF) complicated atrial or ventricular arrhythmia .Methods: A total of 168 CHF patients with atrial or ventricular arrhythmia treated in our hospital from 2017 were randomly and equally divided into metoprolol group (re‐ceived metoprolol based on routine treatment ) and combined treatment group (received irbesartan based on metoprolol group) , both groups were treated for three months .LVEF , left ventricular posterior wall thickness (LVPWT) , interven‐tricular septal thickness (IVST) before and after treatment , therapeutic effect were observed and compared between two groups.Results: Total effective rate of combined treatment group was significantly higher than that of metoprolol group (90.5% vs.73.8%) , P＝ 0.005. Compared with before treatment , there was significant rise in LVEF [ (55.16 ± 6.52)% vs.(64.24 ± 8.72)%] , and significant reductions in LVPWT [ (14.72 ± 1.78) mm vs.(13.27 ± 1.14) mm] , IVST [ (10.18 ± 1.15) mm vs.(9.12 ± 0.64) mm] in combined treatment group after treatment , P＝0.001 all ;and compared with metoprolol group after three‐month treatment , there was significant rise in LVEF [ (56.13 ± 6.15)%vs.(64. 24 ± 8.72)%] , and significant reductions in LVPWT [ (14. 35 ± 1. 23) mm vs.(13.27 ± 1.14) mm] and IVST [(9. 88 ± 0.85) mm vs.(9. 12 ± 0. 64) mm] in combined treatment group , P＝0. 001 all.There was no signif‐icant difference in incidence rate of adverse between two groups , P＝ 0.799. Conclusion: Irbesartan combined metoprolol possess significant therapeutic effect on patients with CHF complicated atrial or ventricular arrhythmia with good safety .Inhibition on ventricular remodeling may be its main mechanism .